CELLS, PROTEINS *and* BIOPROCESSING

Agenda

17th-19th June 2014
London, UK

EuroSciCon

This three day event will discuss three main topics

- Cell Culture Technology Event: Recent advances, future prospect
- Therapeutic proteins and antibodies: from design to function
- Bioprocess development: Discussing facilitation of industrial uptake

With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking.

This event has CPD accreditation

www.regonline.co.uk/Biopro2014

Contents

Program Outline 6

Day 1: Cell Culture Technology Event: Recent advances, future prospect 6

Session Chair: Dr John Davis, University of Hertfordshire; Vice-Chairman of ESACT-UK 6

Day 2: Therapeutic proteins and antibodies: from design to function 6

Session Chair: Dr Sophia Karagiannis , Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London School of Medicine, UK 6

Day 3: Bioprocess development: Discussing facilitation of industrial uptake 6

Session Chair: Ajoy Velayudhan 6

Agenda 7

Day 1: Cell Culture Technology Event: Recent advances, future prospect 7

Introduction by the Chair 7

If you think ignorance is bliss, you're more stupid than you look. 7

Real time, label-free characterisation of live cells in monolayer culture using high resolution, multi-modal light microscopy 7

New methods to identified amino acids, peptides and transjunctional proteins: Co-culture transwell system and mass spectrometry. 7

Human stem cells for disease modelling and tissue reconstruction - promises and challenges 7

Introducing a Novel liquid 3 Dimensional Scaffold for Culturing Cells in 3D 7

3D Cell Cultures & New Reagents for Improved Cellular Viability Quantitation 7

Biofabrication technologies for 3D cell culture systems 7

3D-tetraculture system mimicking the cellular organization at the alveolar barrier. 7

3D in vitro model of a functional epidermal permeability barrier from hESC and iPSC 7

Day 2: Therapeutic proteins and antibodies: from design to function 8

Introduction by the Chair 8

Therapeutic IgE antibodies: enhanced effector functions for cancer therapy 8

Developing of long acting glycoprotein hormones using gene fusion and gene transfer: from bench to clinics 8

Quantum dot- conjugated antibodies as diagnostic and therapeutic tools for cancer imaging and treatment 8

Selection of isotype for immunomodulatory anti-cancer antibodies 8

Targeting immune- checkpoints in cancer: Novel mechanistic insights on the role of antibody/Fc receptor interactions 8

Protein based nano and micro particles for biological applications 8

Measurements' protocol for the investigation of physicochemical and conformational stability and aggregation kinetics of therapeutic IgGs 8

Day 3: Bioprocess development: Discussing facilitation of industrial uptake 9

Introduction by the Chair 9

Micro-cariers: its role in reducing the cost, time, and efforts towards industrial cells proliferation and protein productions 9

High-Throughput and Miniaturisation in Process Development 9

Xanthine Oxidase might serve as a target therapeutic molecule for the treatment of stroke 9

Integration of high-throughput data and mathematical modelling in bioprocess engineering 9
Discussion session 9
New integrated approach to online process monitoring and control in Cell Culture applications 9
Integrated Single-Use Technologies for Continuous MAb Processing 9
Micro-Matrix, the next generation in microbioreactors for high throughout processing 9
About the Speakers 10
Day 1 10
Melissa Mather 10
Maria D. Mayan, ... 10
Patrizia Ferretti, ... 10
Anthony Mitchell Davies' 10
Lucy Wheatley, ... 10
Lorenzo Moroni 11
Arno Gutleb 11
Anastasia Petrova, ... 11
Day 2 11
Fuad Fares 11
Weiming Xu 11
Ann White 11
Dr. Sergio Quezada 12
Deepak Kalaskar 12
Ali Aboel Dahab 12
Day 3 12
Ali Hilal-Alnaqbi, ... 12
Adrian Haines, ... 12
Kristine Danielyan, ... 12
Berno Lüpkes, ... 12
Stephen Cross, ... 13
Mark Peacock, ... 13
Discussion Sessions 13
Session breaks 13
Frequently asked questions about our events 14
Is the delegate list available? 14
Can I have the speakers slides? 14
Can I have a notepad? 14
How can I keep up to date with Euroscicon Events? 14
I don't want my photograph on any Euroscicon promotional material 14
Is there WIFI? 14
Can I have a CPD certificate? 14

Program Outline

Day 1: Cell Culture Technology Event: Recent advances, future prospect

Session Chair: Dr John Davis, University of Hertfordshire; Vice-Chairman of ESACT-UK

John Davis is senior visiting Lecturer in Biotechnology at the University of Hertfordshire, and Vice-Chairman of the UK Branch of the European Society for Animal Cell Technology (ESACT-UK). After a degree in Biochemistry at Sheffield, he moved in 1974 to Renato Dulbecco's laboratory where he was initiated into the art of cell culture. Following PhD studies in Leicester, he moved to Switzerland, working with both Norman Iscove and Georges Köhler, the latter starting him on his many years of research into the use of monoclonal antibodies in therapy. After a further postdoctoral position, at the University of Cambridge where he worked on the early stages of the development of Campath (Alemtuzumab; now also known as Lemtrada), he made the transition to industry, working first for PA Technology and then (for nearly 20 years) for the Bio-Products Laboratory. In 2007 he made the transition back to academia. In addition to undergraduate and postgraduate teaching, he now runs open courses on Basic Cell Culture and Intermediate/Advanced Cell Culture. He has served on both the UKCCCR subcommittee on the Use of Cell Lines in Cancer Research, and the EC task force on Good Cell Culture Practice. In addition he has edited a number of books on cell culture, including Basic Cell Culture:A Practical Approach, and (with Glyn Stacey) Medicines from Animal Cell Culture. His most recent book is Animal Cell Culture: Essential Methods, which was published in March 2011 by Wiley-Blackwell.

Day 2: Therapeutic proteins and antibodies: from design to function

Session Chair: Dr Sophia Karagiannis , Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London School of Medicine, UK

Sophia Karagiannis is a translational cancer immunologist specialising in antibody therapies for melanoma, ovarian and breast carcinomas. She received BA and MS degrees at Rutgers University, USA, having received scholarship awards and a teaching assistantship (1987, 1991), and a PhD at King's College London in Biochemistry under SERC and SmithKline Beecham-funded scholarships (1995). She subsequently developed immunotherapeutic strategies for cancer and inflammatory diseases in academic and biotechnology environments in London and Cambridge as a postdoctoral associate and scientific investigator. She was appointed as NIHR Senior Research Fellow in 2007 and presently leads her own research group as Head of Cancer Antibody Discovery and Immunotherapy at King's College London, focused on dissecting humoral immunity in cancer and leading research into tumourtargeting mechanisms of IgE antibodies and Th2 responses in cancer. Sophia co-founded the International Task Force on AllergoOncology and has pioneered IgE therapeutics for solid tumours. Her research and development initiative on the first IgE class antibody for cancer therapy is conducted in close collaboration with clinical and academic groups at King's College London and the CRUK Drug Development Office.

Day 3: Bioprocess development: Discussing facilitation of industrial uptake.

Session Chair: Ajoy Velayudhan is one of the first EPSRC Manufacturing Fellows, and works as a Principal Research Fellow in the Department of Biochemical Engineering at University College London. He has worked in the biotechnology industry in the USA for 10 years, including process development positions at Johnson & Johnson and Bristol-Myers Squibb; prior to this, he was an academic in the USA. His current research focus is the development of whole-bioprocess models that integrate cell culture, purification, and lyophilisation. A critical component of seamlessly integrating models for these different unit-operations is the evaluation, and principled prioritisation, of data obtained at different scales.

Agenda (Talk times include 5 – 10 minutes for questions)

Day 1: Cell Culture Technology Event: Recent advances, future prospect		
09:30 – 10:15	**Exhibitions open**	Registration and Refreshments
10:15 – 11:00	**Introduction by the Chair** **If you think ignorance is bliss, you're more stupid than you look.**	*Dr John Davis*, University of Hertfordshire, UK
11:00 – 11:30	**Real time, label-free characterisation of live cells in monolayer culture using high resolution, multi-modal light microscopy**	*Dr. Melissa Mather*, Principal Research Fellow, Institute of Biophysics, Imaging and Optical Science, University of Nottingham, UK
11:30 – 12:00	**Session Break**	Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition
12:00 – 12:30	**New methods to identified amino acids, peptides and transjunctional proteins: Co-culture transwell system and mass spectrometry.**	*Dr Maria D. Mayan*, Biomedical Research Center (INIBIC), Universitario A Coruña, Spain
12:30 – 13:00	**Human stem cells for disease modelling and tissue reconstruction - promises and challenges**	*Dr Patrizia Ferretti*, Group Leader, UCL Institute of Child Health, Stem Cell and Regenerative Medicine Section
13:00 – 13:50	**Session Break**	Lunch, Poster viewing, Sponsors exhibition
13:50 – 14:10	**Discussion session**	
14:10 – 14:40	**Introducing a Novel liquid 3 Dimensional Scaffold for Culturing Cells in 3D**	*Dr Anthony Mitchell Davies,* Director of INCHSA, Dept Clinical Medicine Trinity College Dublin, Ireland
14:40 – 15:10	**3D Cell Cultures & New Reagents for Improved Cellular Viability Quantitation**	*Dr Lucy Wheatley*, Field Application Specialist, Promega UK
15:10 – 15:30	**Session Break**	Refreshments Last poster viewing Last Sponsors exhibition
15:30 – 16:00	**Biofabrication technologies for 3D cell culture systems**	*Dr Lorenzo Moroni,* Associate Professor, University of Twente, Tissue Regeneration Department, The Netherlands
16:00 – 16:30	**3D-tetraculture system mimicking the cellular organization at the alveolar barrier.**	*Dr Arno C. Gutleb,* Chef de projet, Centre de Recherche Public - Gabriel Lippmann, Luxembourg
16:30 – 17:00	**3D in vitro model of a functional epidermal permeability barrier from hESC and iPSC**	*Dr Anastasia Petrova,* Research Fellow Immunobiology Unit, UCL Institute of Child Health/ Assisted Conception Unit, King's College London, UK
17:00	**Chairman's Summing Up**	**Close of Session**

Day 2: Therapeutic proteins and antibodies: from design to function		
09:30 – 10:15	**Exhibitions open**	Registration and Refreshments
10:15 – 10:30	**Introduction by the Chair**	*Dr Sophia Karagiannis*, Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London School of Medicine, UK
10:30 – 11:00	**Therapeutic IgE antibodies: enhanced effector functions for cancer therapy**	*Dr Sophia Karagiannis,* Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King's College London School of Medicine, UK
11:00 – 11:30	**Developing of long acting glycoprotein hormones using gene fusion and gene transfer: from bench to clinics**	*Professor. Fuad Fares,* University of Haifa, Israel
11:30 – 12:00	**Session Break**	Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition
12:00 – 12:30	**Quantum dot- conjugated antibodies as diagnostic and therapeutic tools for cancer imaging and treatment**	*Dr Weiming Xu*, CEO, London Biotech Ltd, UK
12:30 – 13:00	**Selection of isotype for immunomodulatory anti-cancer antibodies**	*Dr Ann White*, Senior Research Fellow, University of Southampton, UK
13:00 – 14:00	**Session Break**	Lunch, Poster viewing, Sponsors exhibition
14:00 – 15:00	**Discussion session**	
15:00 – 15:30	**Session Break**	Refreshments, Last poster viewing, Last Sponsors exhibition
15:30 – 16:00	**Targeting immune-checkpoints in cancer: Novel mechanistic insights on the role of antibody/Fc receptor interactions**	*Dr Sergio A. Quezada,* Immune Regulation and Tumour Immunotherapy Group, UCL Cancer Institute, UK
16:00 – 16:30	**Protein based nano and micro particles for biological applications**	*Deepak Kalaskar,* Centre for Nanotechnology and Tissue Engineering, UCL , London
16:30 – 17:00	**Measurements' protocol for the investigation of physicochemical and conformational stability and aggregation kinetics of therapeutic IgGs**	*Dr* Ali A. Dahab BSc, MSc, PhD, MBPS, MRSC, FRSM Microseparation Group Pharmaceutical Sciences Research Division King's College, UK
17:00	**Chairman's Summing Up**	**Close of Session**

Day 3: Bioprocess development: Discussing facilitation of industrial uptake

09:30 – 10:15	**Exhibitions open**	Registration and Refreshments
10:15 – 10:30	**Introduction by the Chair**	*Dr Ajoy Velayudhan*, Principal Research Fellow & EPSRC Manufacturing Fellow, Department of Biochemical Engineering, University College London, United Kingdom
10:30 – 11:00	**Micro-cariers: its role in reducing the cost, time, and efforts towards industrial cells proliferation and protein productions**	*Dr Ali Hilal-Alnaqbi,* Assistant Professor UAEU, Visiting Assistant Professor, Harvard, USA
11:00 –12:00	**High-Throughput and Miniaturisation in Process Development**	*Dr Adrian Haines*, Senior Principal Scientist, Lonza Biologics plc, UK
12:00 – 12:30	**Session Break**	Speakers' photo, Refreshments, Poster viewing, Sponsors exhibition
12:30 – 13:00	**Xanthine Oxidase might serve as a target therapeutic molecule for the treatment of stroke**	*Dr. Kristine Danielyan, National Academy of Science, Armenia*
13:00 – 13:30	**Integration of high-throughput data and mathematical modelling in bioprocess engineering**	*Dr Ajoy Velayudhan*, Principal Research Fellow & EPSRC Manufacturing Fellow, Department of Biochemical Engineering, University College London, United Kingdom
13:30 – 14:30	**Session Break**	Lunch, Poster viewing, Sponsors exhibition
14:30 – 15:00	**Discussion session**	
15:00 – 15:30	**New integrated approach to online process monitoring and control in Cell Culture applications**	*Mr Berno Lüpkes*, Sales Manger UK/Ireland, Hamilton Robotics
15:30 – 16:00	**Session Break**	Refreshments, Last poster viewing Last Sponsors exhibition
16:00 – 16:30	**Integrated Single-Use Technologies for Continuous MAb Processing**	*Dr. Stephen Cross,* EU Process Development Scientist Manager, BioManufacturing Science Network, Merck Millipore
16:30 – 17:00	**Micro-Matrix, the next generation in microbioreactors for high throughout processing**	*Mark Peacock,* Applikon Biotechnology UK.
17:00	**Chairman's Summing Up**	**Close of Meeting**

About the Speakers

Day 1

Melissa Mather, Principal Research Fellow, Institute of Biophysics, Imaging and Optical Science, University of Nottingham, UK

Dr Melissa Mather is a Principal Research Fellow in the Institute of Biophysics, Imaging and Optical Science, University of Nottingham. Her research expertise lies in the non-invasive monitoring of cells and tissue. Dr Mather has an established track record of research and publications detailing the application of ultrasound, optical and opto-acoustic techniques for characterisation of live cells, biomaterials and tissue constructs used in Regenerative Medicine. Dr Mather is currently a holder of an EPSRC Career Acceleration Fellowship developing ultrasound nano-transducers for tracking of cells used in Regenerative Medicine and co-Investigator on the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine.

Maria D. Mayan, earned her bachelor's degree in Pharmacy from University of Santiago de Compostela (USC) in 2000 and her Ph.D. in Biology from Complutense University of Madrid in 2006 under the supervision of Professor Jorge Bernardo Schvartzman. Before starting the PhD, she worked for 3 years (1999-2002) in the group headed by Dr. Felix Camiña and Professor S. Rodriguez-Segade at the USC. She carried out two post-doctoral stays in London, at the Imperial College London and Clinical Sciences Centre in the group of Professor Richard Festenstein and Professor Luis Aragon. In July 2008, she has been named Honorary Research Fellow at the Imperial College London. The results that María D. Mayán obtained during her first post-doctoral stay lead to the discovery of the transcriptional regulation of frataxin gene using primary lymphocytes from healthy individuals and patients with ataxia. The results will likely lead to the development of new therapeutic targets for Friedreich's ataxia disorder. During her second post-doctoral stay, she was investigating the functions of transcription and RNA Polymerase II on nuclear architecture, chromosome segregation and DNA replication. She now leads The Cartilage Biology Research Group. In January 2010, she joined the Division of Rheumatology, coordinated by Dr. Francisco Blanco, under the Isidro Parga Pondal research program from Xunta de Galicia. Her research group is focused on the study of the physiopathology and molecular mechanisms responsible for the development of osteoarthritis. Her research group has obtained novel results crucial to understand the physiology of articular chondrocytes in cartilage that will help to understand the physiopathology of cartilage-related diseases. [ResearchGate] [ORDIC]

Patrizia Ferretti, Group Leader, UCL Institute of Child Health, Stem Cell and Regenerative Medicine Section

Patrizia Ferretti's research focus over the last few years has been on regeneration of tissues with limited regenerative capability, neural and craniofacial skeletal tissues, in the context of normal and abnormal development and cell plasticity. Her overall aim is to better understand mechanisms underlying lack of regenerative capability and harness them to develop new approaches to induce repair. Her group has identified a number of cellular and molecular mechanisms which play a role in response to injury and repair in in vivo and in vitro models. Current effort in her group is also devoted to developing novel 3-dimensional models for modelling human neural damage and relevant to skeletal tissue repair.

Anthony Mitchell Davies' research has been focused on the development of advanced in vitro c ell based models for almost 2 decades. During his early research work, Dr Davies was primarily involved in the development of specialized bioreactor cell based models utilising primary adult cardiomyocytes which were specifically designed for use in the study of the molecular events that occur during the acute and chronic phases of heart disease. Latterly Dr Davies has been active in rapidly growing field of high content screening and analysis (HCS/A) where he has been responsible for the setting up and running of one of the first purpose built academic screening centres in Europe (INCHSA) which is based in the prestigious department of Clinical Medicine Trinity College Dublin. Since its opening INCHSA has gained recognition internationally as a centre of excellence for both advanced technology development and training in the area of cell based screening. As part of these activities Dr Davies was key in the setting up and running of the first academic course specifically focused on the use of HCS/A technologies in Biomedical Research. Most recently Dr Davies has developed and commercialized a suite of novel micro-plate Bio-reactor technologies and liquid 3D cellular scaffolds specifically designed for use in automated Drug discovery.

Lucy Wheatley, Field Application Specialist, Promega UK

Dr Lucy is Field Application Specialist for Promega UK, providing expert support and advice across a wide range of molecular and cellular applications to researchers in the scientific community. Prior to joining Promega Dr Wheatley worked at the Wellcome Trust Gurdon Institute and obtained a PhD in Genetics.

Lorenzo Moroni studied Biomedical Engineering at Polytechnic of Milan, Italy, and Nanoscale Sciences at Chalmers Technical University, Sweden. In 2001, he visited the lab of Professor Luke Lee at University of California Berkley, where he worked on microfabrication technologies for tissue engineering applications. After receiving his Ph.D in 2006 at University of Twente with Professor van Blitterswijk's group on 3D scaffolds for cartilage and osteochondral regeneration, he worked at Johns Hopkins University as a post-doctoral fellow focusing on hydrogels and stem cells. In 2008, he was appointed the R&D director of the Musculoskeletal Tissue Bank of Rizzoli Orthopaedic Institute in Bologna, Italy, where he investigated the use of stem cells from alternative sources for cell banking, and the development of novel bioactive scaffolds for bone and cartilage regeneration. He joined again the Tissue Regeneration department in 2009 as a principal investigator. Currently, his research interests aim at generating new libraries of bioactive scaffolds to recruit and deliver stem cells in situ and control their differentiation. He is also a co-founder of the biotech company Screvo B.V., which is committed to the production of animal implantable 3D high through-put screening systems.

Arno Gutleb graduated from the University of Veterinary Medicine Vienna, Austria and holds a Dr. env. sci. with specialization in toxicology from Wageningen University, The Netherlands and is a European registered toxicologist (ERT). He is visiting professor at the Universidad Andres Bello, Santiago de Chile and project leader for toxicology at the Centre de Recherche Public - Gabriel Lippmann in Luxembourg.

Anastasia Petrova, Research Fellow, Immunobiology Unit, UCL Institute of Child Health/ Assisted Conception Unit, King's College London, UK
Anastasia Petrova is a Research Fellow at the Institute of Child Health, UCL working on the development and validation of translational strategies for gene therapy approaches in inherited skin diseases. She has obtained her PhD in Gene, Cell and Tissue Therapy from King's College London where she has been working on directed differentiation of pluripotent stem cells into functional keratinocytes, the predominant cell type of the outermost layer of the skin.
Her research interest is in gene and stem cell approaches for treatment of genetic skin diseases, in particular, using pluripotent stem cell technology for development of physiologically-relevant cellular models for drug screening and functional analysis.

Day 2

Fuad Fares is a director of PROLOR Biotech and its Chief Scientific Officer and head of the Molecular Biology Division, Biochemical Research Unit, Department of Biochemistry and Molecular Genetics at the Carmel Medical Center in Haifa, Israel. While doing postdoctoral work at Washington University (St. Louis, Missouri), Professor Fares worked with Prof. Irving Boime to develop PROLOR's platform technology. Dr. Fares was elected a research member at the Rappaport Institute for Research in Medical Sciences (Technion - Israel Institute of Technology, Bruce Rappaport Faculty of Medicine, 1995-1997). He is the recipient of several awards, including the prestigious Lindner Prize of the Israel Endocrine Society (2004), and the Shawers Prize of the Israel Endocrine Society (1997) and the author of over forty scientific articles and chapters in scientific textbooks. He is a member of two Israeli organizations: the Israel Endocrine Society and the Israeli Society for Biochemistry and Molecular Biology. In the United States, Dr. Fares is a member of the Clinical Ligand Assay Society (CLAS), and the New York Academy of Sciences. He is a graduate of the department of pharmacology at the Technion - Israel Institute of Technology (Haifa, Israel).

Weiming Xu is the Chief Executives Officer in London Biotech Ltd. He obtained his PhD degree from the Imperial Cancer Research Fund/Chinese Academy of Sciences program in London. His first postdoctoral training was with Sir Bruce Ponder University of Cambridge. He then worked in Babraham Institute and later has taken the Senior Research Fellow position in the University College London, working on nitric oxide signaling with Sir Salvador Moncada. From 2009, he moved to the University of Sheffield as a Senior Research Associate. He has published more than 50 scientific papers in peer-reviewed journals with over 1,400 citations (ISI).

Ann White is a Senior Research Fellow within the Cancer Sciences Unit, University of Southampton. Her research is focused upon the optimisation of anti-cancer therapeutic mAb through the manipulation of mAb structure. Ann received a BSc in Applied Biology from the University of Hertfordshire in 1987 and a PhD in Molecular and Cellular Biology from the MRC Clinical Research Centre, Harrow in 1991. She then worked in Texas for 10 years on lipoprotein metabolism. After a career break with her young children Ann joined Professor Martin Glennie's group in 2005 and is part of a CRUK funded antibody discovery programme

Dr. Sergio Quezada is a Professorial Research Fellow at UCL Cancer Institute where he heads the Immune Regulation and Tumour Immunotherapy Laboratory. Prior to this, he worked in Dr. James Allison's laboratory at Memorial Sloan-Kettering Cancer Center studying the mechanisms governing anti-tumour T-cell immunity, and how these mechanisms can be manipulated for the generation of potent anti-tumour immune responses. His research interests are around the study of the mechanism of action of anti-CTLA-4 and other immune-modulatory antibodies targeting co-inhibitory and co-stimulatory pathways. Dr Quezada is a CRUK Career Development fellow and the recipient of a Cancer Research Institute investigator Award.

Deepak Kalaskar has a multidisciplinary background in engineering, chemistry and biology. He has special interests in surface coating technologies. He worked for 1 year after completion of Bachelor's degree in R&D with BASF coatings Pvt Ltd. Due to his interests in biological coatings; he pursued a funded PhD at University of Manchester, UK investigating effect of small Amino acids on cellular behaviour. Following his PhD, he worked at various universities in UK and Belgium on number of developmental research projects which include high throughput culture for embryonic stem cells, Nanomaterials coatings for orthopaedic implants, protein nanotubes for drug delivery applications, 3D printing of cells using inject printing and osteochondral plug for knee repair.
Currently, Dr Kalaskar heads Msc course in Burns, Plastic and Reconstructive surgery at University College London (UCL) and actively involved in research on nanotechnology and tissue engineering solutions for artificial organs such as intracranial Stents, breast Implants, synthetic nose, ear, skin and bone tissue engineering.

Ali Aboel Dahab is a researcher and lecturer at the pharmaceutical research division, King's College London. He is a member of several professional bodies and the editorial board of some scientific journals. He has worked as a consultant in the area of biopharmaceutical and toxicological analysis at deltaDot Ltd. He has a special interest in pharmacology, biopharmaceuticals, toxicological and chiral analysis, biological spectroscopy and the development of analytical techniques. He has made a promising modification to Capillary Electrophoresis which is yet to be published.

Day 3

Ali Hilal-Alnaqbi, Assistant Professor UAEU, Visiting Assistant Professor, Harvard, USA

Adrian Haines, Senior Principal Scientist, Lonza Biologics plc, UK
Adrian is a Senior Principal Scientist in the Process Development Sciences Dept. at Lonza Biologics Research and Development facilities in Slough, UK. Adrian has lead projects to introduce automation and new technologies and processes for the development of cell lines for biopharmaceutical manufacture.
He has been involved in cell culture and the production of monoclonal antibodies for nearly 28 years and has worked at Celltech, Therexsys, Cobra Research, ML Laboratories and Lonza. He holds a degree from Imperial College and a PhD from St Thomas's Hospital Medical School, London.

Kristine Danielyan, National Academy of Science, Armenia. Kristine Danielyan has received her MS degree in Biochemistry (1999) and PhD in Biology (2003) in Armenia after DAAD supported short-term work performance in cooperation with the Department of Pharmacology of Marburg University (Germany). The first PostDoc position in the field of experimental neurology was performed in Cerebral Vascular Disease Research Center, Department of Neurology (School of Medicine, University of Miami, 2003-2004). After the completion of her second PostDoc position (Postdoctoral Fellowship, Institute for Environmental Medicine, School of Medicine, University of Pennsylvania, USA) she was back to Armenia where she worked as a Senior Researcher and leaded a small group in the H. Buniatian Institute of Biochemistry, National Academy of Sciences. She is an author and co-author of more than 20 manuscripts and patents; has received awards and different types of grants from IBRO, ANSEF and Academy of Science of Armenia.

Berno Lüpkes, Sales Manger UK/Ireland, Hamilton Robotics
Berno Lüpkes, Sales Manager of Hamilton products in the UK and Ireland since relocating to the UK from Germany early 2010. He is responsible for the sales and support of Hamilton's line of process sensors and has been working with numerous companies primarily from the Pharma/Biotech industry to provide process sensor solutions and services for upstream and downstream processes. As an expert in the intelligent sensors for the measurement of dissolved oxygen, pH, biomass volume (viable and total cell density), conductivity and redox Berno provides a consultative approach to ensure clients receive optimum solutions.

Stephen Cross, EU Process Development Scientist Manager, BioManufacturing Science Network, Merck Millipore. He manages a team of process development scientists within the Merck Millipore Biomanufacturing Sciences Network (BSN). The BSN is a global customer support network bringing the best scientific and technical support to Merck Millipore customers. Steve is based in the UK and (with his team) offers remote and onsite support to customers in the U.K., Ireland, BeNeLux and Nordics. Steve has 10 years experience with Merck Millipore. Prior to that he spent 9 years with a number of biotech companies in the U.K. and holds a PhD from the University of Kent (Canterbury, U.K.).

Mark Peacock, Applikon Biotechnology UK.
Mark Peacock is the Bioreactor Specialist for Applikon Biotechnology UK. Prior to joining Applikon Mark had over seven years industrial experience working in the biopharma sector as a Senior Upstream Research Scientist. Mark has worked on a vast number of different bioprocesses that ultimately resulted in large scale manufacture; therefore he has acquired a vast amount of experience in the areas of R&D, scale up, scale down and cGMP Manufacture. Mark graduated from Durham University with a B.Sc (Hons) in Biomedical Science

Discussion Sessions

The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.

Session breaks

All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you

Lunch

- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
- We have a range of vegetarian dishes which are separated from the meat and fish dishes

Frequently asked questions about our events

Is the delegate list available?

Yes this is available to everyone who attends the event and our sponsors.
It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event.
You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

Can I have the speakers slides?

We cannot give out the slides from our speaker's presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

Can I have a notepad?

Notepads and pens are provided in the delegate bags and at the registration desk

How can I keep up to date with Euroscicon Events?

To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com

I don't want my photograph on any Euroscicon promotional material

Please let our tech person know

Is there WIFI?

Yes, please ask registration for log in details.

Can I have a CPD certificate?

CPD certificates will be available in the exhibition hall after lunch

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations